Level Four Advisory Services LLC Has $6.98 Million Position in Novo Nordisk A/S (NYSE:NVO)

Level Four Advisory Services LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 17.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,159 shares of the company's stock after selling 16,610 shares during the quarter. Level Four Advisory Services LLC's holdings in Novo Nordisk A/S were worth $6,981,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. GQG Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after buying an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $404,910,000. Loomis Sayles & Co. L P boosted its position in Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Sustainable Growth Advisers LP lifted its position in Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after acquiring an additional 1,021,498 shares during the last quarter. Finally, Amundi grew its stake in shares of Novo Nordisk A/S by 26.4% during the fourth quarter. Amundi now owns 3,311,456 shares of the company's stock worth $283,615,000 after acquiring an additional 692,567 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Remove Ads

Novo Nordisk A/S Stock Down 1.1 %

NYSE:NVO traded down $0.81 on Friday, hitting $69.36. 5,852,065 shares of the company's stock traded hands, compared to its average volume of 5,563,763. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1 year low of $69.18 and a 1 year high of $148.15. The firm has a 50-day moving average price of $82.33 and a 200-day moving average price of $98.89. The company has a market cap of $311.23 billion, a PE ratio of 21.08, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 47.72%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NVO. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Friday, March 21st. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.